Key details
Phase
Safety & dosing / Large-scale testing
Enrollment target
~2,442 participants
Primary completion
October 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 60 Years
Last updated December 2023